Measurement of Impact of Hemafuse, an Autologous Blood Transfusion Device

Organization: 
Sisu Global Health
Organization Location: 
Baltimore, Maryland, USA

Life-saving surgery often cannot be scheduled if there is no access to blood, making this a critical gap in patient care, particularly impacting mothers suffering from ruptured ectopic pregnancy. For cases of internal bleeding, there is the option to salvage and recycle a patient's own blood (autotransfusion). The simple, manual methods currently used across Sub-Saharan Africa, employing a soup ladle and gauze, save lives but are unsafe to the patient and clinician. Hemafuse will provide access to blood in cases of internal bleeding and be a safer, faster, more accessible alternative. Through a previous SL@B Seed award, the project developed and tested the safety of the Hemafuse, including a clinical study in Ethiopia. 

The goal for SL@B Validation is to establish the impact and limitations of Hemafuse across countries for ruptured ectopic pregnancy and other trauma. Sisu proposes a 3 site study at St. Paul Millennium Medical College (Ethiopia), Komfo Anokye Teaching Hospital (Ghana), and/or Cameroon Baptist Health Services (Cameroon) in partnership with University of Alabama. Comparability of sites will be ensured through collaboration with GSSHealth. This study will provide data on how the device impacts patients; how different regions and levels of hospitals affects use of the device; and how to effectively train users. The results of this clinical study will inform which factors to focus on for scale, such as urban or peri-urban hospitals and health systems familiar or unfamiliar with autotransfusion.

See video